Andrea Fontanella
Overview
Explore the profile of Andrea Fontanella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
606
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Di Micco P, Imparato M, Lubrano G, Iannuzzo D, Fontanella L, Improta L, et al.
Medicina (Kaunas)
. 2021 Jan;
57(2).
PMID: 33498929
COVID-19 has been associated with a hypercoagulable state and thrombotic events. Venous thromboembolism has been the most commonly reported type of thrombosis but also arterial thrombosis and disseminated intravascular coagulation...
12.
Pieralli F, Vannucchi V, Nozzoli C, Augello G, Dentali F, De Marzi G, et al.
BMC Infect Dis
. 2021 Jan;
21(1):116.
PMID: 33494707
Background: The burden of cardiovascular (CV) complications in patients hospitalised for community-acquired pneumonia (CAP) is still uncertain. Available studies used different designs and different criteria to define CV complications. We...
13.
Russo V, Cardillo G, Viggiano G, Mangiacapra S, Cavalli A, Fontanella A, et al.
Front Med (Lausanne)
. 2020 Dec;
7:569567.
PMID: 33330530
The use of anticoagulant therapy with heparins decreased mortality in hospitalized patients with severe coronavirus disease 2019 (COVID-19). Even if enoxaparin and fondaparinux have the same clinical indication for venous...
14.
Cagnazzo C, Besse M, Manfellotto D, Minghetti P, Cazzaniga S, Cottini L, et al.
Tumori
. 2020 Dec;
107(1):6-11.
PMID: 33297885
The coronavirus disease 2019 (COVID-19) pandemic has stressed the importance of health research as never before. In the specific domain of clinical research, the effort to rapidly find responses to...
15.
Russo V, Cardillo G, Viggiano G, Mangiacapra S, Cavalli A, Fontanella A, et al.
J Cardiovasc Pharmacol
. 2020 Oct;
76(4):369-371.
PMID: 33027192
The use of heparin has been shown to decrease the mortality in hospitalized patients with severe COVID-19. The aim of our study was to evaluate the clinical impact of venous...
16.
Di Micco P, Di Micco G, Russo V, Poggiano M, Salzano C, Bosevski M, et al.
J Blood Med
. 2020 Jul;
11:237-241.
PMID: 32694923
While waiting for the vaccine and/or the best treatment for COVID19, several drugs have been identified as potential adjuvant drugs to counteract the viral action. Several drugs, in fact, have...
17.
Dentali F, Pomero F, Di Micco P, La Regina M, Landini F, Mumoli N, et al.
Eur J Intern Med
. 2020 Jun;
80:54-59.
PMID: 32474052
Introduction: Pulmonary embolism (PE) prevalence in acute exacerbations of COPD is highly variable. Methods: To investigate the prevalence and risk factors of PE in patients hospitalized in Departments of Internal...
18.
Dentali F, Fontanella A, Cohen A, Simonetti M, Parretti L, Marconi E, et al.
Thromb Haemost
. 2020 Apr;
120(4):692-701.
PMID: 32289864
Background: Most episodes of venous thromboembolism (VTE) occurred in primary care. To date, no score potentially able to identify those patients who may deserve an antithrombotic prophylaxis has been developed....
19.
Agnelli G, Becattini C, Meyer G, Munoz A, Huisman M, Connors J, et al.
N Engl J Med
. 2020 Mar;
382(17):1599-1607.
PMID: 32223112
Background: Recent guidelines recommend consideration of the use of oral edoxaban or rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However, the benefit of these oral agents...
20.
Perticone F, Fontanella A, Ferrara N, Ferrari A
Intern Emerg Med
. 2020 Feb;
15(7):1359.
PMID: 32107721
In the original publication of the article.